-
1
-
-
84887033779
-
A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study
-
Aerts JG, Codrington H, Lankheet NA, et al (2013). A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 study. Ann Oncol, 24, 2860-5.
-
(2013)
Ann Oncol
, vol.24
, pp. 2860-2865
-
-
Aerts, J.G.1
Codrington, H.2
Lankheet, N.A.3
-
2
-
-
84926406694
-
Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study
-
Auliac JB, Chouaid C, Greiller L, et al (2014). Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study. Lung Cancer, 85, 415-19.
-
(2014)
Lung Cancer
, vol.85
, pp. 415-419
-
-
Auliac, J.B.1
Chouaid, C.2
Greiller, L.3
-
3
-
-
84885458948
-
Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small cell lung cancer patients with unknown EGFR mutational status
-
Aydiner A, Yildiz I, Seyidova A (2013). Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small cell lung cancer patients with unknown EGFR mutational status. Asian Pac J Cancer Prev, 14, 3255-61.
-
(2013)
Asian Pac J Cancer Prev
, vol.14
, pp. 3255-3261
-
-
Aydiner, A.1
Yildiz, I.2
Seyidova, A.3
-
4
-
-
74949117339
-
Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer
-
Dahabreh IJ, Linardou H, Siannis F, et al (2010).Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res, 16, 291-303.
-
(2010)
Clin Cancer Res
, vol.16
, pp. 291-303
-
-
Dahabreh, I.J.1
Linardou, H.2
Siannis, F.3
-
5
-
-
64649091718
-
Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small cell lung cancer
-
Di Maio M, Chiodini P, Georgoulias V, et al (2009). Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small cell lung cancer. J Clin Oncol, 27, 1836-43.
-
(2009)
J Clin Oncol
, vol.27
, pp. 1836-1843
-
-
Di Maio, M.1
Chiodini, P.2
Georgoulias, V.3
-
6
-
-
84901244141
-
A randomized phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer
-
Dittrich C, Papai-Szekely Z, Vinolas N, et al (2014).A randomized phase II study of pemetrexed versus pemetrexed+erlotinib as second-line treatment for locally advanced or metastatic non-squamous non-small cell lung cancer. Eur J Cancer, 50, 1571-80.
-
(2014)
Eur J Cancer
, vol.50
, pp. 1571-1580
-
-
Dittrich, C.1
Papai-Szekely, Z.2
Vinolas, N.3
-
7
-
-
74949133020
-
Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking towards 2012
-
Gandara DR, Mack PC, Li T, Lara PN Jr, Herbst RS (2009). Evolving treatment algorithms for advanced non-small-cell lung cancer: 2009 looking towards 2012. Clin Lung Cancer, 10, 392-4.
-
(2009)
Clin Lung Cancer
, vol.10
, pp. 392-394
-
-
Gandara, D.R.1
Mack, P.C.2
Li, T.3
Lara, P.N.4
Herbst, R.S.5
-
8
-
-
41149096042
-
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells
-
Giovannetti E, Lemos C, Tekle C, et al (2008). Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol, 73, 1290-300.
-
(2008)
Mol Pharmacol
, vol.73
, pp. 1290-1300
-
-
Giovannetti, E.1
Lemos, C.2
Tekle, C.3
-
9
-
-
84887434792
-
Chemotherapy with erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors
-
Goldberg SB, Oxnard GR, Digumarthy S, et al (2013). Chemotherapy with erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors. Oncologist, 18, 1214-20.
-
(2013)
Oncologist
, vol.18
, pp. 1214-1220
-
-
Goldberg, S.B.1
Oxnard, G.R.2
Digumarthy, S.3
-
10
-
-
84884955771
-
Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR TKI-responsive, advanced non-small cell lung cancer (NSCLC) that subsequently progresses
-
Halmos B, Pennell NA, Otterson GA, et al (2013). Erlotinib beyond progression study: Randomized phase II study comparing chemotherapy plus erlotinib with chemotherapy alone in EGFR TKI-responsive, advanced non-small cell lung cancer (NSCLC) that subsequently progresses. J Clin Oncol, 31, (suppl; abstr 8114).
-
(2013)
J Clin Oncol
, vol.31
-
-
Halmos, B.1
Pennell, N.A.2
Otterson, G.A.3
-
11
-
-
2442661845
-
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
-
Hanna N, Shepherd F, Fossella F, et al (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 22, 1589-97.
-
(2004)
J Clin Oncol
, vol.22
, pp. 1589-1597
-
-
Hanna, N.1
Shepherd, F.2
Fossella, F.3
-
12
-
-
1542713370
-
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2
-
Herbst RS, Giaccone G, Schiller JH, et al (2004). Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol, 22, 785-94.
-
(2004)
J Clin Oncol
, vol.22
, pp. 785-794
-
-
Herbst, R.S.1
Giaccone, G.2
Schiller, J.H.3
-
13
-
-
24944440830
-
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer
-
Herbst RS, Prager D, Hermann R, et al (2005). TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol, 23, 5892-9.
-
(2005)
J Clin Oncol
, vol.23
, pp. 5892-5899
-
-
Herbst, R.S.1
Prager, D.2
Hermann, R.3
-
14
-
-
0041876133
-
Measuring inconsistency in meta-analyses
-
Higgins JP, Thompson SG, Deeks JJ, et al (2003). Measuring inconsistency in meta-analyses. BJM, 327, 557-60.
-
(2003)
BJM
, vol.327
, pp. 557-560
-
-
Higgins, J.P.1
Thompson, S.G.2
Deeks, J.J.3
-
15
-
-
80052972204
-
A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer
-
Hirsch FR, Kabbinavar F, Eisen T, et al (2011). A randomized, phase II, biomarker-selected study comparing erlotinib to erlotinib intercalated with chemotherapy in first-line therapy for advanced non-small-cell lung cancer. J Clin Oncol, 29, 3567-73.
-
(2011)
J Clin Oncol
, vol.29
, pp. 3567-3573
-
-
Hirsch, F.R.1
Kabbinavar, F.2
Eisen, T.3
-
16
-
-
0029914622
-
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
-
Jadad AR, Moore RA, Carroll D, et al (1996). Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Control Clin Trials, 17, 1-12.
-
(1996)
Control Clin Trials
, vol.17
, pp. 1-12
-
-
Jadad, A.R.1
Moore, R.A.2
Carroll, D.3
-
17
-
-
84863892117
-
Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial
-
Janne PA, Wang X, Socinski MA, et al (2012). Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. J Clin Oncol, 30, 2063-9.
-
(2012)
J Clin Oncol
, vol.30
, pp. 2063-2069
-
-
Janne, P.A.1
Wang, X.2
Socinski, M.A.3
-
18
-
-
77955635233
-
Cancer statistics, 2010
-
Jemal A, Siegel R, Xu J, Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300.
-
(2010)
CA Cancer J Clin
, vol.60
, pp. 277-300
-
-
Jemal, A.1
Siegel, R.2
Xu, J.3
Ward, E.4
-
19
-
-
56249109644
-
Gefitinib versus docetaxel in previously treated on-small-cell lung cancer (INTEREST): a randomized phase III trial
-
Kim ES, Hirsh V, Mok T, et al (2008). Gefitinib versus docetaxel in previously treated on-small-cell lung cancer (INTEREST): a randomized phase III trial. Lancet, 372, 809-18.
-
(2008)
Lancet
, vol.372
, pp. 809-818
-
-
Kim, E.S.1
Hirsh, V.2
Mok, T.3
-
20
-
-
84884906715
-
Three-arm randomized controlled phase 2 study comparing pemetrexed and erlotinib to as second-line treatment for never-smokers with non-squamous non-small cell lung cancer
-
Lee DH, Lee JS, Kim SW, et al (2013). Three-arm randomized controlled phase 2 study comparing pemetrexed and erlotinib to as second-line treatment for never-smokers with non-squamous non-small cell lung cancer. Eur J Cancer, 49, 3111-21.
-
(2013)
Eur J Cancer
, vol.49
, pp. 3111-3121
-
-
Lee, D.H.1
Lee, J.S.2
Kim, S.W.3
-
21
-
-
68549140332
-
Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC
-
Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S (2009). Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat Rev Clin Oncol, 6, 352-66.
-
(2009)
Nat Rev Clin Oncol
, vol.6
, pp. 352-366
-
-
Linardou, H.1
Dahabreh, I.J.2
Bafaloukos, D.3
Kosmidis, P.4
Murray, S.5
-
22
-
-
84925450073
-
Randomized phase II study of pharmacodynamic separation (PDS) of pemetrexed (Pem) and erlotinib (Erl) versus pem alone in patients (pts) with advanced non-small cell lung cancer (NSCLC)
-
Li TH, Piperdi B, Walsh WV, et al (2013). Randomized phase II study of pharmacodynamic separation (PDS) of pemetrexed (Pem) and erlotinib (Erl) versus pem alone in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol, 31, 8097.
-
(2013)
J Clin Oncol
, vol.31
, pp. 8097
-
-
Li, T.H.1
Piperdi, B.2
Walsh, W.V.3
-
23
-
-
37349080007
-
Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation
-
Mahaffey CM, Davies AM, Lara PN Jr, et al (2007). Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation. Clin Lung Cancer, 8, 548-53.
-
(2007)
Clin Lung Cancer
, vol.8
, pp. 548-553
-
-
Mahaffey, C.M.1
Davies, A.M.2
Lara, P.N.3
-
24
-
-
32044450314
-
Use of novel second-line targeted therapies in non-small cell lung cancer
-
Massarelli E, Herbst RS (2006). Use of novel second-line targeted therapies in non-small cell lung cancer. Semin Oncol, 33, 9-16.
-
(2006)
Semin Oncol
, vol.33
, pp. 9-16
-
-
Massarelli, E.1
Herbst, R.S.2
-
26
-
-
84893206526
-
Combination of EGFR-TKIs and chemotherapy as first-line therapy for advanced NSCLC: a meta-analysis
-
OuYang PY, Su Z, Mao YP, Deng W, Xie FY (2013). Combination of EGFR-TKIs and chemotherapy as first-line therapy for advanced NSCLC: a meta-analysis. PLoS One, 13, 79000.
-
(2013)
PLoS One
, vol.13
, pp. 79000
-
-
OuYang, P.Y.1
Su, Z.2
Mao, Y.P.3
Deng, W.4
Xie, F.Y.5
-
27
-
-
84887111018
-
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins
-
Remon J, Morán T, Majem M, et al (2014). Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins. Cancer Treat Rev, 40, 93-101.
-
(2014)
Cancer Treat Rev
, vol.40
, pp. 93-101
-
-
Remon, J.1
Morán, T.2
Majem, M.3
-
28
-
-
0037050352
-
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer
-
Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8.
-
(2002)
N Engl J Med
, vol.346
, pp. 92-98
-
-
Schiller, J.H.1
Harrington, D.2
Belani, C.P.3
-
29
-
-
0034069620
-
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
-
Shepherd FA, Dancey J, Ramlau R, et al (2000). Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol, 18, 2095-103.
-
(2000)
J Clin Oncol
, vol.18
, pp. 2095-2103
-
-
Shepherd, F.A.1
Dancey, J.2
Ramlau, R.3
-
30
-
-
84894094209
-
Subsequent treatment choices with acquired resistance to EGFR-TKIs in non-small cell lung cancer: restore after a drug holiday or switch to another EGFR-TKI?
-
Song T, Yu W, Wu SX (2014). Subsequent treatment choices with acquired resistance to EGFR-TKIs in non-small cell lung cancer: restore after a drug holiday or switch to another EGFR-TKI? Asian Pac J Cancer Prev, 15, 205-13.
-
(2014)
Asian Pac J Cancer Prev
, vol.15
, pp. 205-213
-
-
Song, T.1
Yu, W.2
Wu, S.X.3
-
31
-
-
65349124698
-
Current treatments for advanced stage non-small cell lung cancer
-
Stinchcombe TE, Socinski MA (2009). Current treatments for advanced stage non-small cell lung cancer. Proc Am Thorac Soc, 6, 233-41.
-
(2009)
Proc Am Thorac Soc
, vol.6
, pp. 233-241
-
-
Stinchcombe, T.E.1
Socinski, M.A.2
-
32
-
-
77953394930
-
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor
-
Takezawa K, Okamoto I, Tanizaki J, et al (2010). Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor. Mol Cancer Ther, 9, 1647-56.
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 1647-1656
-
-
Takezawa, K.1
Okamoto, I.2
Tanizaki, J.3
-
33
-
-
84887016439
-
Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboringsensitizing-EGFR mutations in the presence of gefitinib
-
Tsai CM, Chen JT, Chiu CH, et al (2013). Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboringsensitizing-EGFR mutations in the presence of gefitinib. Lung Cancer, 82, 305-12.
-
(2013)
Lung Cancer
, vol.82
, pp. 305-312
-
-
Tsai, C.M.1
Chen, J.T.2
Chiu, C.H.3
-
34
-
-
79951775017
-
Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?
-
Tsai CM, Chen JT, Stewart DJ, et al (2011). Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed? J Thorac Oncol, 6, 559-68.
-
(2011)
J Thorac Oncol
, vol.6
, pp. 559-568
-
-
Tsai, C.M.1
Chen, J.T.2
Stewart, D.J.3
-
35
-
-
84863837004
-
Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation
-
Tsai CM, Chiu CH, Chang KT, et al (2012). Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation. J Thorac Oncol, 7, 1218-27.
-
(2012)
J Thorac Oncol
, vol.7
, pp. 1218-1227
-
-
Tsai, C.M.1
Chiu, C.H.2
Chang, K.T.3
|